Skip to content
TrialScanner

NCT05128942

A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH

Phase 2TerminatedSPRBLead

Registry record

Lead sponsor
Spruce Biosciences
Conditions
Congenital Adrenal Hyperplasia; 21-OHD
Primary completion
Jan 31, 2025Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05128942 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05128942: A Phase 2 Study to Evaluate... | TrialScanner